The University of Turku , located in Turku in southwestern Finland, is the second largest university in the country as measured by student enrollment, after University of Helsinki. It was established in 1920 and also has faculties at Rauma, Pori and Salo. The university is a member of the Coimbra Group. Wikipedia.
University of Turku | Date: 2016-09-01
The invention is based on a finding that silencing CIP2A (KIAA1524) gene sensitizes cancer cells for apoptosis-inducing activity of certain small molecule chemotherapeutic agents. Thus, the invention is directed to a respective combination therapy, sensitization method and pharmaceutical compositions. The invention further relates to a method of selecting cancer therapy for a subject on the basis of CIP2A and p53 expression and/or protein activity in a sample obtained from said subject.
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 3.97M | Year: 2017
MMbio will bridge the classically separate disciplines of Chemistry and Biology by assembling leading experts from academia and non-academic partners (industry, technology transfer & science communication) to bring about systems designed to interfere therapeutically with gene expression in living cells. Expertise in nucleic acid synthesis, its molecular recognition and chemical reactivity is combined with drug delivery, cellular biology and experimental medicine. This project represents a concerted effort to make use of a basic and quantitative understanding of chemical interactions to develop and deliver oligonucleotide molecules of utility for therapy. Our chemical biology approach to this field is ambitious in its breadth and represents a unqiues opportunity to educate young scientists across sectorial and disciplinary barriers. Training will naturally encompass a wide range of skills, requiring a joint effort of chemists and biologists to introduce young researchers in a structured way to and array of research methodologies that no single research grouping could provide. The incorporation of early-stage and later stag ebiotechnology enterprises ensures that commercialisation of methodologies as well as the drug development process is covered in this ITN. We hope that MMBio will train scientists able to understand both the biological problem and the chemistry that holds the possible solution and develop original experimental approaches to stimulate European academic and commercial success in this area.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-30-2015 | Award Amount: 5.01M | Year: 2016
SMARTool aims at developing a platform based on cloud technology, for the management of patients with coronary artery disease (CAD) by standardizing and integrating heterogeneous health data, including those from key enabling technologies. The platform includes existing multiscale and multilevel ARTreat (FP7-224297) models of coronary plaque progression based on non-invasive coronary CT angiography (CCTA) and fractional flow reserve computation, refined by heterogeneous patient-specific non-imaging data (history, lifestyle, exposome, biohumoral data, genotyping) and cellular/molecular markers derivable from a microfluidic device for on-chip blood analysis. SMARTool models will be applied and validated by historical and newly acquired CCTA imaging plus non-imaging health data from the EVINCI project (FP7-222915) population. SMARTool cloud-based platform, through Human Computer Interaction techniques, 3D visual representation and artery models, will use heterogeneous data in a standardized format as input, providing as output a CDSS - assisted by a microfluidic device as a point of care testing of inflammatory markers for: i) Patient specific CAD stratification - existing models, based on clinical risk factors, will be implemented by patient genotyping and phenotyping to stratify patients with non-obstructive CAD, obstructive CAD and those without CAD, ii) site specific plaque progression prediction - existing multiscale and multilevel ARTreat tools of CAD progression prediction will be refined by genotyping and phenotyping parameters and tested by baseline and follow CCTA and integrated by non-imaging patient-specific data, iii) patient-specific CAD diagnosis and treatment - life style changes, standard or high intensity medical therapy and a virtual angioplasty tool to provide the optimal stent type(s) and site(s) for appropriate deployment.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: INFRAIA-01-2016-2017 | Award Amount: 10.51M | Year: 2017
RadioNet is a consortium of 28 institutions in Europe, Republic of Korea and South Africa, integrating at European level world-class infrastructures for research in radio astronomy. These include radio telescopes, telescope arrays, data archives and the globally operating European Network for Very Long Baseline Interferometry (EVN). RadioNet is de facto widely regarded to represent the interests of radio astronomy in Europe. A comprehensive, innovative and ambitious suite of actions is proposed that fosters a sustainable research environment. Building on national investments and commitments to operate these facilities, this specific EC program leverages the capabilities on a European scale. The proposed actions include: - Merit-based trans-national access to the RadioNet facilities for European and for the first time also for third country users; and integrated and professional user support that fosters continued widening of the community of users. - Innovative R&D, substantially enhancing the RadioNet facilities and taking leaps forward towards harmonization, efficiency and quality of exploitation at lower overall cost; development and delivery of prototypes of specialized hardware, ready for production in SME industries. - Comprehensive networking measures for training, scientific exchange, industry cooperation, dissemination of scientific and technical results; and policy development to ensure long-term sustainability of excellence for European radio astronomy. RadioNet is relevant now, it enables cutting-edge science, top-level R&D and excellent training for its European facilities; with the Atacama Large Millimetre Array (ALMA) and the ESFRI-listed Square Kilometre Array (SKA) defined as global radio telescopes, RadioNet assures that European radio astronomy maintains its leading role into the era of these next-generation facilities by involving scientists and engineers in the scientific use and innovation of the outstanding European facilities.
Agency: Cordis | Branch: H2020 | Program: CSA | Phase: INFRASUPP-01-2016 | Award Amount: 2.00M | Year: 2017
RISCAPE will provide systematic, focused, high quality, comprehensive, consistent and peer-reviewed international landscape analysis report on the position and complementarities of the major European research infrastructures in the international research infrastructure landscape. To achieve this, RISCAPE will establish a close links with a stakeholder panel representing the main user groups of the report, including representatives from ESFRI, the OECD and Member state funding agencies to ensure usability and the focus of the Report. It will also benefit from close co-operation with other projects and initiatives in the European research infrastructures development to ensure consistency with the existing landscape work. Particularly, RISCAPE builds on the European Research Infrastructures (RIs) in the ESFRI landscape report (2016) and on the landscape analysis done or currently underway in the H2020 cluster projects. RISCAPE leverages the experts on the European RIs with extensive knowledge on the disciplines involved and RI development in Europe and the project benefits from the contacts and tools developed in the cluster- and international RI collaboration projects to maximize the discipline-specific usability of the results. A key factor in the RISCAPE analysis is that the complementarities will be analyzed in a way which is natural and suitable for the discipline and RI in question. The resulting Report and the used methods will be independently peer reviewed to maximize the usability and objectivity of the information provided for the EU strategic RI development and policy. The project answers directly to the European Commission strategy on EU international cooperation in research and innovation, particularly on the need to obtain objective information in order to help implement the (EC) strategic approach.
Yegutkin G.G.,University of Turku
Critical Reviews in Biochemistry and Molecular Biology | Year: 2014
Extracellular nucleotides and nucleosides mediate diverse signaling effects in virtually all organs and tissues. Most models of purinergic signaling depend on functional interactions between distinct processes, including (i) the release of endogenous ATP and other nucleotides, (ii) triggering of signaling events via a series of nucleotide-selective ligand-gated P2X and metabotropic P2Y receptors as well as adenosine receptors and (iii) ectoenzymatic interconversion of purinergic agonists. The duration and magnitude of purinergic signaling is governed by a network of ectoenzymes, including the enzymes of the nucleoside triphosphate diphosphohydrolase (NTPDase) family, the nucleotide pyrophosphatase/phosphodiesterase (NPP) family, ecto-5′-nucleotidase/CD73, tissue-nonspecific alkaline phosphatase (TNAP), prostatic acid phosphatase (PAP) and other alkaline and acid phosphatases, adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP). Along with "classical" inactivating ectoenzymes, recent data provide evidence for the co-existence of a counteracting ATP-regenerating pathway comprising the enzymes of the adenylate kinase (AK) and nucleoside diphosphate kinase (NDPK/NME/NM23) families and ATP synthase. This review describes recent advances in this field, with special emphasis on purine-converting ectoenzymes as a complex and integrated network regulating purinergic signaling in such (patho)physiological states as immunomodulation, inflammation, tumorigenesis, arterial calcification and other diseases. The second part of this review provides a comprehensive overview and basic principles of major approaches employed for studying purinergic activities, including spectrophotometric Pi-liberating assays, high-performance liquid chromatographic (HPLC) and thin-layer chromatographic (TLC) analyses of purine substrates and metabolites, capillary electrophoresis, bioluminescent, fluorometric and electrochemical enzyme-coupled assays, histochemical staining, and further emphasizes their advantages, drawbacks and suitability for assaying a particular catalytic reaction. © 2014 Informa Healthcare USA, Inc.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-02-2015 | Award Amount: 5.99M | Year: 2016
The goal of this multidisciplinary project is to comprehensively characterise high-grade serous ovarian cancer (HGS-OvCa) at single-cell level, identify the best combination of drug combination to kill HGS-OvCa populations and commercialise a predictive biomarker kit for finding the right therapeutic regimen to the right patient. This project takes an advantage on prospectively and longitudinally collected fresh sample specimens from multiple anatomic sites of HGS-OvCa patients with metastatic disease. Fluorescence activated cell sorting and recently developed mass cytometry are used to identify subpopulations in HGS-OvCa tumors. This is followed by single-cell analysis at genetic and transcriptomics levels, and ex vivo drug screening experiments. These data will be used to establish network models to predict the most effective combinatorial treatments. The key results will be validated with existing HGS-OvCa data together with prospective and retrospective cohorts and in vivo models. The clinically most actionable treatment suggestions from our modelling efforts will be translated to HGS-OvCa patient care. Ovarian cancer kills more than 40,000 women in Europe every year due to lack of effective and long-lasting therapeutic regimens. HERCULES presents an innovative strategy to suggest effective treatments that lead to a marked decrease in ovarian cancer deaths and reduce the number of expensive but inefficient treatments. Our approach paves the way to move beyond the current trial-and-error clinical assessment of drug combinations toward more systematic prediction of the most effective drug combinations for each patient. The proposed approach will be a major breakthrough in systems medicine and will benefit individual ovarian cancer patients and the health-care system through more effective treatments, and the diagnostic and pharmaceutical industry through tools for better stratified clinical trials, and novel treatment and diagnostic modalities.
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 2.14M | Year: 2017
The overall objective of Glyco Imaging is to develop novel assays for detection of glycans as biomarkers associated with aggressive and metastatic cancer forms. The assays will be developed for biomarker detection in blood, urine, cells and tissue. Molecularly Imprinted Polymers (MIPs), or plastic antibodies, have been developed for targeting the human glycan sialic acid (SA), or Neu5Ac. The efficiency of the Neu5Ac specific SAMIPs targeted to the biomarker SA in different solvents (methanol, water, phosphate buffer) will be exploited. The non-human Neu5Gc, which is incorporated into human glycoconjugates through dietary sources such as red meat, and shown to be involved in malignant cell transformation in humans, will also be investigated by using highly specific Neu5Gc-SAMIPs. The imaging and detection techniques used will be based on fluorescence, 3D-viewing of cancer cells by digital holographic microscopy and magnetic separation columns. The results in this research consortium will lead to major technological advances having impact on 1) health care, since it will develop more accurate and reliable diagnostics of aggressive and metastatic cancers, 2) drug discovery allowing a faster and cheaper biomarker targeting and detection; and 3) biochemistry research laboratories in resulting in improved understanding of glycan expression in cancer, with emphasis on aggressive metastatic cancer. The training of researchers will be performed by a consortium consisting of 6 partners with biomedical, imaging and particle synthesis skills (4 groups, one institution, one technology company). This forms the basis for a very competent interdisciplinary training program with high quality in both education and research. 8 early stage researchers (ESRs) working on specific tasks within 5 work packages will follow a rich training program providing a well-balanced spectrum of scientific, business and entrepreneurial skills.
Agency: Cordis | Branch: H2020 | Program: IA | Phase: ICT-22-2016 | Award Amount: 6.34M | Year: 2017
Next-Lab intends to change the educational landscape of science and technology education in Europe on a very large scale. The project offers a unique and extensive collection of interactive online (virtual and remote) laboratories that, through a process of mixing and re-use, can be straightforwardly and efficiently combined with dedicated support tools (learning apps) and multimedia material to truly form open, cloud-based, shareable educational resources with an embedded pedagogical structure. Next-Lab offers extensive opportunities for localisation and personalisation together with analytics facilities monitoring students progress and achievements. Next-Lab is designed to rely on full co-creation with users in combination with rapid development and testing cycles. Next-Lab builds on the highly successful (FP7) Go-Lab project that already offers online labs, inquiry learning apps, and authoring facilities for inquiry learning. To amplify the existing impact to the next-level innovation stage, Next-Lab extends the Go-Lab system with tools for the learning of 21st century skills, facilities for self- and peer-assessment and portfolio development, as well as opportunities to include learning by modeling. Next-Lab will cover secondary and also primary education, to ensure an early positive attitude towards science and technology and the continuous availability of innovative learning material throughout students school career. To guarantee long-term impact, Next-Lab also addresses the teachers of the future by its presence in pre-service teacher training programs throughout Europe. To evaluate its impact, Next-Lab combines usage data analysis techniques for very large-scale pilots with in-depth, qualitative, case-based, assessments. Next-Lab prepares for a following sustainable stage of the product. As it builds upon and extends existing networks of teachers, professional associations, and policymakers, the impact of Next-Lab will be massive.
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 2.63M | Year: 2017
The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC). The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy. Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach: 1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms. 2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools. 3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources. We will train young scientists to apply multiple omics technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.